KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Change in Inventory (2016 - 2025)

Historic Change in Inventory for Supernus Pharmaceuticals (SUPN) over the last 14 years, with Q3 2025 value amounting to $12.9 million.

  • Supernus Pharmaceuticals' Change in Inventory rose 38105.99% to $12.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $135000.0, marking a year-over-year increase of 10076.5%. This contributed to the annual value of -$15.8 million for FY2024, which is 15869.07% down from last year.
  • Supernus Pharmaceuticals' Change in Inventory amounted to $12.9 million in Q3 2025, which was up 38105.99% from -$4.9 million recorded in Q2 2025.
  • Over the past 5 years, Supernus Pharmaceuticals' Change in Inventory peaked at $12.9 million during Q3 2025, and registered a low of -$6.9 million during Q3 2023.
  • Moreover, its 5-year median value for Change in Inventory was $1.0 million (2021), whereas its average is $728631.6.
  • Its Change in Inventory has fluctuated over the past 5 years, first surged by 260666.67% in 2021, then tumbled by 25142.0% in 2024.
  • Quarter analysis of 5 years shows Supernus Pharmaceuticals' Change in Inventory stood at $5.2 million in 2021, then skyrocketed by 120.12% to $11.6 million in 2022, then crashed by 143.52% to -$5.0 million in 2023, then skyrocketed by 36.61% to -$3.2 million in 2024, then soared by 506.02% to $12.9 million in 2025.
  • Its Change in Inventory stands at $12.9 million for Q3 2025, versus -$4.9 million for Q2 2025 and -$4.7 million for Q1 2025.